Currently, there are 76.50M common shares owned by the public and among those 75.74M shares have been available to trade.
The company’s stock has a 5-day price change of -9.14% and -10.88% over the past three months. ASPN shares are trading 29.21% year to date (YTD), with the 12-month market performance up to 195.51% higher. It has a 12-month low price of $6.62 and touched a high of $33.15 over the same period. ASPN has an average intraday trading volume of 2.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.68%, -20.95%, and -5.00% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Aspen Aerogels Inc. (NYSE: ASPN) shares accounts for 92.43% of the company’s 76.50M shares outstanding.
It has a market capitalization of $1.57B and a beta (3y monthly) value of 2.15. The stock’s trailing 12-month PE ratio is 1605.51, while the earnings-per-share (ttm) stands at $0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.78% over the week and 7.94% over the month.
Earnings per share for the fiscal year are expected to increase by 123.03%, and 222.37% over the next financial year.
Looking at the support for the ASPN, a number of firms have released research notes about the stock. Barclays stated their Overweight rating for the stock in a research note on August 06, 2024, with the firm’s price target at $27. ROTH MKM coverage for the Aspen Aerogels Inc. (ASPN) stock in a research note released on March 06, 2024 offered a Buy rating with a price target of $22. The Benchmark Company was of a view on March 20, 2023 that the stock is Buy, while Canaccord Genuity gave the stock Buy rating on October 21, 2022, issuing a price target of $20. The Benchmark Company on their part issued Buy rating on December 10, 2021.
